// App-Quantinova.ai

AB0778 : ASSOCIATION BETWEEN PATIENT-REPORTED OUTCOMES AND DISEASE ACTIVITY IN BIMEKIZUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS

Researchers

Presenter

  • L. Gossec

Principal Investigators

  • P. J. Mease

  • A. B. Gottlieb

  • A. Ogdie

  • D. Assudani

  • J. Coarse

  • B. Ink

  • L. C. Coates

Medical Centers

  • Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France

  • Icahn School of Medicine at Mount Sinai Hospital - New York - United States of America

  • University of Pennsylvania, Philadelphia, United States of America

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Raleigh, United States of America

  • University of Oxford, Oxford, United Kingdom

Locations

  • France

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02969525

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved